Evelo Biosciences Sees Unusually Large Options Volume (NASDAQ:EVLO)

Evelo Biosciences, Inc. (NASDAQ:EVLO) was the recipient of unusually large options trading on Wednesday. Stock traders acquired 1,885 put options on the company. This represents an increase of 1,101% compared to the typical volume of 157 put options.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Walleye Capital LLC bought a new position in shares of Evelo Biosciences in the first quarter valued at $38,000. Morgan Stanley increased its holdings in shares of Evelo Biosciences by 22.6% in the fourth quarter. Morgan Stanley now owns 78,892 shares of the company’s stock valued at $127,000 after buying an additional 14,567 shares in the last quarter. State Street Corp increased its holdings in shares of Evelo Biosciences by 3.3% in the first quarter. State Street Corp now owns 578,861 shares of the company’s stock valued at $1,962,000 after buying an additional 18,469 shares in the last quarter. Shay Capital LLC bought a new position in shares of Evelo Biosciences in the fourth quarter valued at $30,000. Finally, Barclays PLC increased its holdings in shares of Evelo Biosciences by 654.2% in the fourth quarter. Barclays PLC now owns 22,641 shares of the company’s stock valued at $36,000 after buying an additional 19,639 shares in the last quarter. Institutional investors own 0.31% of the company’s stock.

Evelo Biosciences Price Performance

EVLO opened at $0.04 on Thursday. The company has a market capitalization of $834,171.00, a price-to-earnings ratio of 0.00 and a beta of 2.03. Evelo Biosciences has a 1-year low of $0.03 and a 1-year high of $13.93. The business has a 50 day moving average price of $0.05 and a two-hundred day moving average price of $0.43.

Evelo Biosciences Company Profile

Evelo Biosciences, Inc, a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. It is developing EDP1815, a whole-microbe product candidate, which has completed a Phase 2 trial for the treatment of psoriais; and is in Phase 2 clinical trial for the treatment of atopic dermatitis.